Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 18, 2023

BUY
$5.9 - $6.95 $21,240 - $25,020
3,600 Added 13.58%
30,100 $198,000
Q1 2023

Apr 19, 2023

SELL
$6.18 - $7.99 $2,472 - $3,196
-400 Reduced 1.49%
26,500 $179,000
Q4 2022

Jan 24, 2023

SELL
$6.87 - $10.96 $687 - $1,096
-100 Reduced 0.37%
26,900 $199,000
Q3 2022

Oct 19, 2022

SELL
$9.44 - $11.76 $2,832 - $3,528
-300 Reduced 1.1%
27,000 $267,000
Q2 2022

Jul 20, 2022

BUY
$9.31 - $11.84 $1,862 - $2,368
200 Added 0.74%
27,300 $315,000
Q1 2022

Apr 22, 2022

BUY
$10.84 - $16.55 $1,084 - $1,655
100 Added 0.37%
27,100 $305,000
Q4 2021

Jan 14, 2022

BUY
$15.69 - $21.14 $3,138 - $4,228
200 Added 0.75%
27,000 $424,000
Q3 2021

Oct 12, 2021

BUY
$15.35 - $21.27 $26,095 - $36,159
1,700 Added 6.77%
26,800 $459,000
Q2 2021

Jul 16, 2021

BUY
$15.71 - $21.51 $3,142 - $4,302
200 Added 0.8%
25,100 $540,000
Q1 2021

Apr 14, 2021

SELL
$13.42 - $20.28 $4,026 - $6,084
-300 Reduced 1.19%
24,900 $374,000
Q4 2020

Jan 11, 2021

SELL
$9.77 - $13.81 $977 - $1,381
-100 Reduced 0.4%
25,200 $331,000
Q3 2020

Oct 19, 2020

BUY
$9.32 - $12.02 $98,512 - $127,051
10,570 Added 71.76%
25,300 $244,000
Q1 2020

Apr 13, 2020

SELL
$7.5 - $16.8 $26,550 - $59,472
-3,540 Reduced 19.38%
14,730 $153,000
Q4 2019

Jan 17, 2020

SELL
$12.38 - $17.47 $17,703 - $24,982
-1,430 Reduced 7.26%
18,270 $300,000
Q1 2019

Apr 15, 2019

BUY
$17.59 - $31.05 $457 - $807
26 Added 0.13%
19,700 $362,000
Q4 2018

Jan 14, 2019

SELL
$18.97 - $31.47 $66,888 - $110,963
-3,526 Reduced 15.2%
19,674 $514,000
Q3 2018

Oct 16, 2018

BUY
$18.25 - $23.0 $423,400 - $533,600
23,200 New
23,200 $532,000

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $247M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Louisiana State Employees Retirement System Portfolio

Follow Louisiana State Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Louisiana State Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Louisiana State Employees Retirement System with notifications on news.